Who It's For
Built for teams that need
primary intelligence, not summaries
Secondary research on China's biopharma ecosystem is widely available. Primary intelligence — from someone with direct access to the sources, language, and regulatory context — is not.
What We Do
Institutional service lines
All engagements are scoped on a project basis. Contact us to discuss your specific intelligence need.
Competitive Intelligence
Pipeline & Market
Systematic mapping of the competitive landscape for a specific therapeutic area or molecule class in China — approved products, clinical-stage pipeline, development timelines, and strategic positioning of key players.
Due Diligence Support
Asset & Company
Primary intelligence support for investment or licensing due diligence on Chinese biotech assets — clinical data verification, regulatory history, management background, and independent assessment of development claims.
Regulatory Intelligence
NMPA · CDE · Policy
Monitoring and analysis of China's regulatory environment — NMPA policy shifts, CDE review dynamics, priority review designations, and the practical implications for market access timelines and development strategy.
Expert Consultations
GLG · Guidepoint · Dialectica · Third Bridge
Available as a verified subject-matter expert through leading expert networks for structured consultations on China's biopharma ecosystem, clinical genomics, NGS interpretation, and rare disease treatment landscape.
Engagement model: All institutional projects are scoped individually — flat-fee per project or retainer arrangements depending on scope and duration. Contact us to discuss your specific need and receive a proposal within 48 hours.
Why EviGeno
What Western research firms
cannot give you
Most China-focused biopharma research available to Western institutions is secondary intelligence — aggregated from English-language sources, filtered through intermediaries, and often months behind the primary record. It tells you what was already public. It does not tell you what is happening at the source.
EviGeno works from primary sources: NMPA and CDE filings in their original language, ChiCTR registry data, Chinese corporate disclosures, and direct intelligence from the biopharma ecosystem. The combination of clinical genomics training and structured OSINT methodology means findings are not only retrieved — they are interpreted correctly in their clinical and regulatory context.
For institutional clients making decisions on assets, partnerships, or market positioning, the difference between primary and secondary intelligence is not academic. It is the difference between knowing what the data says and knowing what it means.
Discuss a ProjectPrimary source access
NMPA filings, CDE review records, ChiCTR data, and Chinese corporate disclosures — read in original language, not machine-translated summaries
Clinical interpretation layer
Clinical genomics and NGS background means trial data, biomarker claims, and development rationale are assessed with domain fluency — not just catalogued
No conflicts of interest
Independent practice with no investment positions, no advisory relationships with Chinese biotechs, and no incentive to reach any particular conclusion
Fast, project-based delivery
Scoped and delivered on a project basis — no retainer minimums for institutional work, no waiting for a quarterly report cycle
Start a Conversation
Tell us about your project. We respond to all institutional inquiries within one business day.
Within 1 business day for all institutional inquiries. Urgent requests flagged in the subject line are prioritized.